News
1h
Investor's Business Daily on MSNHims & Hers Health Closes In On Buy Point As Earnings LoomHims stock is climbing back from a steep drop within a base. Shares have climbed nearly 29% during the month and outperformed ...
1h
Zacks Investment Research on MSNCan Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the ...
Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...
Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...
1d
Zacks.com on MSNHIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?Virtual healthcare is rapidly evolving, led by Hims & Hers Health, Inc. HIMS and Teladoc Health, Inc. TDOC. HIMS offers a ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most ...
1d
Zacks.com on MSNHims & Hers Health, Inc. (HIMS) Outperforms Broader Market: What You Need to KnowIn the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $58.68, indicating a +1.79% shift from the previous trading day.
Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.
Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results